Drawing for GEMINI PHARMCHEM

USPTO serial 79143952

GEMINI PHARMCHEM

Reviewed by CopyMark Law Group

Status 402
Filing date
Status date
Registration date
Examiner
FALK, JONATHAN ROBERT
Law office
TTAB

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GEMINI PHARMCHEM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Rachel Rudensky

RACHEL RUDENSKY AKERMAN LLP777 SOUTH FLAGLER DRIVESUITE 1100 WEST TOWERWEST PALM BEACH, FL 33401

Goods and services

ClassDescriptionStatusFirst use
001CHEMICALS FOR USE IN INDUSTRY AND SCIENCE, NAMELY, CHEMICAL PREPARATIONS FOR THE MANUFACTURE OF ACTIVE PHARMACEUTICAL INGREDIENTS, ACTIVE PHARMACEUTICAL INGREDIENTS FOR THE MANUFACTURE OF FINISHED PHARMACEUTICALS, ACTIVE CHEMICAL INGREDIENTS AND AGENTS FOR USE IN THE MANUFACTURE OF ACTIVE PHARMACEUTICAL INGREDIENTS, PHARMACEUTICALS, ANTIPARASITICS AND ANTIPARASITIC PREPARATIONS; PRESERVATIVES FOR PHARMACEUTICAL PREPARATIONSABANDONED
005PHARMACEUTICAL AND VETERINARY PREPARATIONS FOR TREATING VARIOUS TYPES OF CANCERS, DISEASES OF THE IMMUNOLOGICAL SYSTEM, NAMELY, AUTO-IMMUNE DISEASES, DISEASES OF THE ALIMENTARY TRACT, METABOLIC DISORDERS AND DISEASES, BLOOD DISEASES, DISEASES OF THE BLOOD FORMING ORGANS, DISEASES OF THE CARDIOVASCULAR SYSTEM, DERMATOLOGICAL DISEASES AND SKIN DISORDERS, DISEASES OF THE GENITO-URINARY SYSTEM AND SEX HORMONE DISORDERS, SYSTEMIC HORMONAL ABNORMALITIES, MUSCULO-SKELETAL SYSTEM DISEASES, NERVOUS SYSTEM DISEASES AND DISORDERS, RESPIRATORY SYSTEM DISEASES, DISEASES OF THE SENSORY ORGANS, AND FOR PREVENTION OF ORGAN REJECTION AFTER TRANSPLANTATION, ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; CHEMICAL PREPARATIONS FOR PHARMACEUTICAL USE, NAMELY, FOR TREATING CANCER AND ONCOLOGY DISEASES, DISEASES OF THE ALIMENTARY TRACT, METABOLIC DISORDERS AND DISEASES, BLOOD DISEASES, DISEASES OF THE BLOOD FORMING ORGANS, DISEASES OF THE CARDIOVASCULAR SYSTEM, DERMATOLOGICAL DISEASES AND SKIN DISORDERS, DISEASES OF THE GENITO-URINARY SYSTEM AND SEX HORMONE DISORDERS, SYSTEMIC HORMONAL ABNORMALITIES, MUSCULO-SKELETAL SYSTEM DISEASES, NERVOUS SYSTEM DISEASES AND DISORDERS, RESPIRATORY SYSTEM DISEASES, DISEASES OF THE SENSORY ORGANS, ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; CHEMICAL REAGENTS FOR MEDICAL OR VETERINARY USE; PHARMACEUTICAL PREPARATIONS FOR MEDICAL USE FOR TREATING CANCER AND ONCOLOGY DISEASES, DISEASES OF THE ALIMENTARY TRACT, METABOLIC DISORDERS AND DISEASES, BLOOD DISEASES, DISEASES OF THE BLOOD FORMING ORGANS, DISEASES OF THE CARDIOVASCULAR SYSTEM, DERMATOLOGICAL DISEASES AND SKIN DISORDERS, DISEASES OF THE GENITO-URINARY SYSTEM AND SEX HORMONE DISORDERS, SYSTEMIC HORMONAL ABNORMALITIES, MUSCULO-SKELETAL SYSTEM DISEASES, NERVOUS SYSTEM DISEASES AND DISORDERS, RESPIRATORY SYSTEM DISEASES, DISEASES OF THE SENSORY ORGANS, ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS; PHARMACEUTICAL PREPARATIONS FOR USE IN CHEMOTHERAPY; ANTIBIOTICS; DIETARY SUPPLEMENTS FOR HUMANS AND ANIMALS; RADIOACTIVE SUBSTANCES FOR USE IN NUCLEAR MEDICINE; ANTIPARASITICS AND ANTIPARASITIC PREPARATIONSABANDONED
035BUSINESS MANAGEMENT SERVICES, NAMELY, REGULATORY SUBMISSION MANAGEMENT, NAMELY, ASSISTING OTHERS IN PREPARING AND FILING APPLICATIONS FOR DRUGS WITH GOVERNMENTAL REGULATORY BODIES; all of the aforementioned services only in relation to pharmaceuticals and chemicals; RETAIL SERVICES, NAMELY, RETAIL STORE SERVICES, MAIL ORDER SERVICES AND ON-LINE RETAIL STORE SERVICES FEATURING ACTIVE PHARMACEUTICAL INGREDIENTS, AND VETERINARY PREPARATIONS, CHEMICAL PREPARATIONS FOR PHARMACEUTICAL PURPOSES, PHARMACEUTICAL PREPARATIONS FOR MEDICAL PURPOSES, DIETARY SUPPLEMENTS FOR HUMANS AND ANIMALS, RADIOACTIVE SUBSTANCES FOR USE IN NUCLEAR MEDICINE; all of the aforementioned services only in relation to pharmaceuticals and chemicalsABANDONED
042scientific and technological services, namely, research, design, evaluations and engineering appraisals in the fields of chemical intermediates, active chemical ingredients provided by engineers and scientists; industrial analysis and research services in the field of chemical intermediates and active chemical ingredients; engineering; research in the field of chemical research; chemical analysis; chemistry services, namely, chemistry consultation, research in the field of chemistry, optimization of chemical processes, analysis for polymorphism determination; biological research; bacteriological research; physics research; chemical research; all of the aforementioned services only in relation to pharmaceuticals and chemicalsABANDONED

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 17, 2024DENANOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 17, 2024DETHDEATH OF INTERNATIONAL REGISTRATION
Aug 31, 2018FINTFINAL DECISION TRANSACTION PROCESSED BY IB
Aug 3, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB
Aug 3, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 3, 2017MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION
Aug 3, 2017ABN4ABANDONMENT - AFTER INTER PARTES DECISION
Aug 3, 2017OP.TOPPOSITION TERMINATED NO. 999999
Aug 3, 2017OP.SOPPOSITION SUSTAINED NO. 999999
Nov 8, 2015RFNTREFUSAL PROCESSED BY IB
Oct 19, 2015OP.IOPPOSITION INSTITUTED NO. 999999
Oct 16, 2015OPNSOPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Oct 16, 2015OPNCOPPOSITION NOTICE (IB REFUSAL) CREATED
Sep 11, 2015OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Aug 26, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Aug 26, 2015OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Aug 3, 2015LIMELIMITATION FROM THE IB EXAMINED AND ENTERED
Jun 23, 2015ETOFEXTENSION OF TIME TO OPPOSE RECEIVED
Jun 23, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 23, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 20, 2015GPNXNOTIFICATION PROCESSED BY IB
Jun 19, 2015LIMGLIMITATION OF GOODS RECEIVED FROM IB
Jun 3, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 3, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jun 3, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 19, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
May 8, 2015EXPTEXPARTE APPEAL TERMINATED
May 8, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
May 8, 2015XAECEXAMINER'S AMENDMENT ENTERED
May 8, 2015GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
May 8, 2015GNEAEXAMINERS AMENDMENT E-MAILED
May 8, 2015CNEAEXAMINERS AMENDMENT -WRITTEN
May 8, 2015DOCKASSIGNED TO EXAMINER
Apr 22, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Apr 22, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 22, 2015ALIEASSIGNED TO LIE
Apr 20, 2015ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 20, 2015EXPIEX PARTE APPEAL-INSTITUTED
Apr 20, 2015JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY
Apr 20, 2015EXAFEXPARTE APPEAL RECEIVED AT TTAB
Oct 27, 2014GNFNNOTIFICATION OF FINAL REFUSAL EMAILED
Oct 27, 2014GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 27, 2014CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Oct 6, 2014DOCKASSIGNED TO EXAMINER
Sep 30, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Sep 30, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 26, 2014ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 26, 2014REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 18, 2014RFNTREFUSAL PROCESSED BY IB
Apr 1, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Apr 1, 2014RFRRREFUSAL PROCESSED BY MPU
Mar 31, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 30, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 25, 2014MAFRAPPLICATION FILING RECEIPT MAILED
Mar 21, 2014DOCKASSIGNED TO EXAMINER
Mar 21, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 20, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB

Frequently asked questions

Related guidance